AN

Allie Nawrat

Allie is an experienced business journalist; she has six years experience in the B2B tech media space. She has been highly commended by WTW as HR journalist of the Year for three years in a row and was an integral part of the Editorial team when UNLEASH won HR Publication of the Year in 2022.

Allie moderates UNLEASH webinars and roundtables, as well as external panels. She also has podcast & video experience, and to date has published over 1,000 pieces for UNLEASH.

    Covers

    Publications

    • pharmaceutical-technology.com
      247 articles
    • UNLEASH
      21 articles
    • Global Risk Regulator
    • Pharmaceutical Technology

    Writes Most On

    ChiefExecutiveOfficerCEOPharmaceuticalIndustryClinicalTrialPandemicCancerVirusVaccineHealthCareOncologyFoodAndDrugAdministrationFDAPipelineTransportCoronavirusDrugDevelopmentAntibodyMedicineEuropeanUnionInfectionGeneResearchAndDevelopmentProteinAstraZenecaNeoplasmBiotechnologyNovartisWorldHealthOrganizationNationalHealthServiceChinaEnzymeInhibitorChemotherapyPublicHealthPfizerNHSEuropePlaceboImmuneSystemImmunotherapyClinicalEndpointDrugDiscoverySARSCoronavirusBloodGeneticsReceptorAntigenListOfLifeSciencesTCellArtificialIntelligenceEUGlobalHealth
    • Most Popular
    • Recent Work
    • Requests
    • Anthropic CEO thinks half of entry-level roles will be eliminated by 2030: How can HR turn this fear into possibility?
      6 Jun—UNLEASH
      UNLEASH asks experts why HR needs to be steering the train as AI disrupts the world of work, particularly at the entry-level. Anthropic's CEO made headlines last week when he predicted that 50% of entry-level jobs will be eliminated by AI within 5 years. How does HR need to respond to alleviate employee fears? UNLEASH sat down with HR experts to find out - could this actually be a great opportunity to transform entry-level work for the better? Dario Amodei, the CEO of AI company Anthropic,...
    • —UNLEASH
    • —UNLEASH
    • Spotlight on BaseLaunch: fostering innovative start-ups in Basel
      10 Jun 2020—pharmaceutical-technology.com
      Life sciences incubator and accelerator BaseLaunch was founded three years ago to support “promising new biotech ventures move from really early academia to being able to do a Series A round,” director of strategy Neil Goldsmith explains. Backed by the three cantons of the Basel area and five large pharmaceutical companies – Basel-based Roche, Roivant and Novartis, as well as Johnson & Johnson and Pfizer – BaseLaunch has supported nine international ventures into Series A or equivalent rounds...

    People Also Viewed